公开(公告)号：WO2023083868A1

公开(公告)日：2023-05-19

申请号：PCT/EP2022/081274

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： SAHIN, Ugur ,  HASSAN, Hariz Iskandar Bin ,  STROBL, Stefan ,  RÖSEMANN, Roman

IPC: A61K31/4745 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/395 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.

公开(公告)号：WO2023046307A1

公开(公告)日：2023-03-30

申请号：PCT/EP2021/076515

申请日：2021-09-27

Applicant: ISOFOL MEDICAL AB

Inventor： TELL, Roger Ingvar ,  SKINTEMO, Lisa Katarina ,  HOLMÉN, Per Emil Jonathan ,  LINDBERG, Per Lennart

IPC: A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61P35/00

Abstract: The present invention relates to the treatment of right-sided colorectal cancer in human populations having a high frequency of poor prognostic factors, including BRAF- and KRAS mutations, which involves administering multiple boluses of [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF) in connection with 5-fluorouracil (5-FU) based chemotherapy.

公开(公告)号：WO2023015526A1

公开(公告)日：2023-02-16

申请号：PCT/CN2021/112315

申请日：2021-08-12

Applicant: 中国科学技术大学

Inventor： 闵元增 ,  翁建平 ,  郝玉浩 ,  李瑞

IPC: C07F15/00 ,  A61K47/55 ,  A61K31/555 ,  A61K31/616 ,  A61K33/243 ,  A61K31/405 ,  A61K31/203 ,  A61K45/06 ,  A61P35/00

Abstract: 本公开提供了一种化合物，该化合物为由铂药和共价连接到铂药的轴向位置的具有解除免疫负调功能的小分子药物形成的孪药，具有式I所示的结构：本公开的孪药在肿瘤部位同时发挥铂药的肿瘤杀伤作用和小分子药物的解除免疫负调的功能，与免疫治疗联合使用，可以有效的提高免疫治疗的响应，显著地提高对肿瘤的治疗效果。本公开中铂类抗癌孪药的制备方法简单。

公开(公告)号：WO2023010080A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/074259

申请日：2022-07-28

Applicant: SEAGEN INC.

Inventor： SCHMITT, Michael ,  GARDAI, Shyra J.

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K31/337 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/655 ,  A61K31/7068 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/75

Abstract: This disclosure relates to methods of treating cancer using a combination of an anti-CD40 antibody such as SEA-CD40, and an anti-PD-1 antibody such as pembrolizumab. The treatment can further include a chemotherapy.

公开(公告)号：WO2022173932A1

公开(公告)日：2022-08-18

申请号：PCT/US2022/015951

申请日：2022-02-10

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： ZHAO, Jean ,  WANG, Qiwei ,  DING, Liya

IPC: A61K31/381 ,  A61K31/337 ,  A61K31/352 ,  A61K31/353 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/452 ,  A61K31/454 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/555 ,  A61K31/6615 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04

Abstract: The present invention relates, in part, to methods for using STING agonists to polarize pro-tumor macrophages in a subject with cancer into anti-tumor macrophages, for example to improve effectiveness of PARP inhibition.

公开(公告)号：WO2022173759A1

公开(公告)日：2022-08-18

申请号：PCT/US2022/015683

申请日：2022-02-08

Applicant: ABLE DERM LLC

Inventor： DREHER, Frank

IPC: A61K31/315 ,  A61K31/555 ,  A61K31/60

Abstract: The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions.

公开(公告)号：WO2022157629A1

公开(公告)日：2022-07-28

申请号：PCT/IB2022/050415

申请日：2022-01-19

Applicant: LUPIN LIMITED

Inventor： BHONDE, Mandar Ramesh ,  PATRA, Sukanya ,  PALLE, Venkata P. ,  KAMBOJ, Rajender Kumar

IPC: A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61K31/517 ,  A61K31/337 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068

Abstract: This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided is a pharmaceutical combination comprising a SOS1 Inhibitor and an additional active ingredient selected from a KRAS inhibitor such as a KRAS G12C inhibitor and a KRAS G12D inhibitor, KRAS G13C inhibitor, and pan KRAS inhibitor; an EGFR inhibitor; an ERK1/2 inhibitor; a BRAF inhibitor; a pan-RAF inhibitor; a MEK inhibitor; a AKT inhibitor; a SHP2 inhibitor; protein arginine methyltransferases (PRMTs) inhibitor such as a PRMTS inhibitor and Type 1 PRMT inhibitor; a PI3K inhibitor; a cyclin -dependent kinase (CDK) inhibitor such as CDK4/6 inhibitor; a FGFR inhibitor; a c-Met inhibitor; a RTK inhibitor; a non-receptor tyrosine kinase inhibitor; a histone methyltransferases (HMTs) inhibitor; a DNA methyltransferases (DNMTs) inhibitor; a Focal Adhesion Kinase (FAK) inhibitor; a Bcr-Abl tyrosine kinase inhibitor; a mTOR inhibitor; a PD1 inhibitor; a PD-L1 inhibitor; CTLA4 inhibitor; and chemotherapeutic agents such as gemcitabine, doxorubicin, cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan and temozolomide.

公开(公告)号：WO2022079085A1

公开(公告)日：2022-04-21

申请号：PCT/EP2021/078277

申请日：2021-10-13

Applicant: HEIDELBERG UNIVERSITY

Inventor： ROMERO-NIETO, Carlos ,  RÖSCH, Saskia ,  HEROLD-MENDE, Christel ,  FERMI, Valentina

IPC: A61K31/555 ,  A61K31/675 ,  A61P35/00 ,  C07F1/12

Abstract: Glioblastoma is one of the most lethal brain tumors. Difficulties for the treatment of glioblastoma involve, among others, the sensitivity of the brain to drugs, the limited brain penetration of chemotherapeutic agents and the resistance of tumor cells to conventional therapies. Provided are specific phosphaphenalene-gold (I) complexes for use as a medicament, especially in the treatment of brain cancer such as glioblastoma, a pharmaceutical composition and a kit comprising such complex.

公开(公告)号：WO2022076762A1

公开(公告)日：2022-04-14

申请号：PCT/US2021/054075

申请日：2021-10-08

Applicant: PAN, Li-Chi ,  WANG, Tzu-Li ,  SHIH, Mei-Wen ,  CHEN, Chi-Yao ,  HONG, Ming-Siang ,  LEE, Matthew

Inventor： PAN, Li-Chi ,  WANG, Tzu-Li ,  SHIH, Mei-Wen ,  CHEN, Chi-Yao ,  HONG, Ming-Siang

IPC: A61K31/555 ,  C07F15/04

Abstract: Disclosed herein are compositions containing an effective amount of a NiSOD or a derivative thereof useful as a prophylactic treatment for hair graying or follicle degeneration. Also disclosed here are methods for treating or mitigating hair graying and/or follicle degeneration.

公开(公告)号：WO2022074014A1

公开(公告)日：2022-04-14

申请号：PCT/EP2021/077470

申请日：2021-10-05

Applicant: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG ,  FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Inventor： ALBRECHT, Volker ,  VON BRIESEN, Hagen ,  SCHEGLMANN, Dietrich ,  GITTER, Burkhard ,  WIEHE, Arno ,  WAGNER, Sylvia ,  GERMANN, Anja ,  STEEN, Dorika ,  WIELAND, Gerhard

IPC: C07D487/22 ,  A61K31/555 ,  A61P31/04 ,  A61P31/12

Abstract: Biologically active compounds are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for phototherapy, including photodynamic therapy, of viral or bacterial infections. As the compounds exhibit also toxicity against targets (bacteria, viruses) without light these biologically active compounds may also be used for the light- independent treatment of such diseases. Embodiments include porphyrins, chlorins, and dihydroxy chlorins as well as their zinc complexes. Also included are embodiments where these compounds are incorporated into liposomal formulations.